Authors
Arkadeep Dhali, Jyotirmoy Biswas, Fayaz Khan, Ashish Sharma, Dushyant S Dahiya, Saikat Mandal, Manideepa Maji
Published in
American journal of clinical oncology. Jun 18, 2026. Epub Jun 18, 2026.
Abstract
The optimal timing of pancreatic enzyme replacement therapy (PERT) after pancreatic surgery for pancreatic cancer remains uncertain. We compared outcomes after early versus delayed PERT initiation in a real-world cohort.
This retrospective cohort study used the TriNetX US Collaborative Network database. Adults with pancreatic cancer undergoing pancreatic surgery were categorized as early PERT if treatment was started within 1 month after surgery, and late PERT if started between 2 and 3 months after surgery. Outcomes were assessed from 90 to 730 days after the index event. Comparative analyses were performed after 1:1 propensity score matching.
Before matching, 3960 patients were identified in the late PERT cohort and 9807 in the early PERT cohort; after matching, 3948 patients were retained in each group. All-cause mortality was similar between the late and early PERT cohorts (1076/3871 [27.8%] vs. 1022/3831 [26.7%]; risk ratio [RR]: 1.042; 95% CI: 0.969-1.121; P=0.270; hazard ratio [HR]: 1.018; 95% CI: 0.935-1.109; log-rank P=0.677). Emergency department visits were also similar (35.7% vs. 34.3%; RR: 1.042; 95% CI: 0.981-1.107; P=0.179). Late PERT was associated with higher risk of diarrhoea (31.0% vs. 28.9%; RR: 1.072; 95% CI: 1.002-1.147; P=0.044) and albumin <3.5 g/dL (62.7% vs. 58.8%; RR: 1.066; 95% CI: 1.029-1.105; P<0.001; HR: 1.076; 95% CI: 1.017-1.139; log-rank P=0.011).
Delayed PERT initiation was not associated with higher mortality or emergency department utilization but was associated with higher diarrhea and hypoalbuminemia risk.
PMID:
42314023
Bibliographic data and abstract were imported from PubMed on 19 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0